Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuemei Luo

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
Mayo Clinic Proceedings|May 7, 2020
Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes MellitusGregory Y H Lip, Allison V Keshishian, Amiee L Kang, et al.
Nature Immunology|May 6, 2020
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formationJun Jacob Hu, Xing Liu, Shiyu Xia, et al.
Science (New York, N.Y.)|January 15, 2026
Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesityDanhui Liu, Chuanli Zhou, Xiaochen Wang, et al.
Science Advances|October 21, 2016
TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1Mohammad B Hossain, Rehnuma Shifat, David G Johnson, et al.
Nature Communications|June 19, 2026
Conformational cycling of the Wntless transporter drives trafficking and secretion of Wnt morphogensYunhui Ge, Taciani de Almeida Magalhaes, Hongjiang Wu, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Feature-Driven Whole-Tissue Imaging with Subcellular ResolutionJinlong Lin, Zach Marin, Xiaoding Wang, et al.
Cardiology in the Young|April 5, 2024
Relationship between syncopal symptoms and head-up tilt test modesShuo Wang, Yali Peng, Yuwen Wang, et al.
Cell Reports Methods|September 3, 2025
Feature-driven whole-tissue imaging with subcellular resolutionJinlong Lin, Zach Marin, Xiaoding Wang, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
Mayo Clinic Proceedings|May 7, 2020
Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes MellitusGregory Y H Lip, Allison V Keshishian, Amiee L Kang, et al.
Nature Immunology|May 6, 2020
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formationJun Jacob Hu, Xing Liu, Shiyu Xia, et al.
Science (New York, N.Y.)|January 15, 2026
Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesityDanhui Liu, Chuanli Zhou, Xiaochen Wang, et al.
Science Advances|October 21, 2016
TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1Mohammad B Hossain, Rehnuma Shifat, David G Johnson, et al.
Nature Communications|June 19, 2026
Conformational cycling of the Wntless transporter drives trafficking and secretion of Wnt morphogensYunhui Ge, Taciani de Almeida Magalhaes, Hongjiang Wu, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Feature-Driven Whole-Tissue Imaging with Subcellular ResolutionJinlong Lin, Zach Marin, Xiaoding Wang, et al.
Cardiology in the Young|April 5, 2024
Relationship between syncopal symptoms and head-up tilt test modesShuo Wang, Yali Peng, Yuwen Wang, et al.
Cell Reports Methods|September 3, 2025
Feature-driven whole-tissue imaging with subcellular resolutionJinlong Lin, Zach Marin, Xiaoding Wang, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Pageof 19